Characteristics of TCM syndrome distribution in patients with metabolic-related fatty liver disease and its correlation with clinical biochemical parameters
YANG Tian-yi,ZONG Xiang-yu.Characteristics of TCM syndrome distribution in patients with metabolic-related fatty liver disease and its correlation with clinical biochemical parameters[J]. Beijing Journal of Traditional Chinese Medicine,2023,42(04):450-453.
YANG Tian-yi,ZONG Xiang-yu.Characteristics of TCM syndrome distribution in patients with metabolic-related fatty liver disease and its correlation with clinical biochemical parameters[J]. Beijing Journal of Traditional Chinese Medicine,2023,42(04):450-453. DOI: 10.16025/j.1674-1307.2023.04.026.
ESLAM M, NEWSOME PN, SARIN SK, et al.A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol,2020,73(1):202-209.
CUI Y, CHANG R, ZHANG T, et al. Chinese herbal formula (CHF03) attenuates non-alcoholic fatty liver disease (NAFLD) through inhibiting lipogenesis and anti-oxidation mechanisms[J]. Front Pharmacol,2019,10:1190.
ZHOU F, ZHOU J, WANG W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis[J]. Hepatology,2019,70(4):1119-1133.
YOUNOSSI ZM. Non-alcoholic fatty liver disease - A global public health perspective[J]. J Hepatol,2019,70(3):531-544.
ZHU JZ, ZHOU QY, WANG YM, et al. Prevalence of fatty liver disease and the economy in China: A systematic review[J]. World J Gastroenterol,2015,21(18):5695-5706.
COHEN JC, HORTON JD, HOBBS HH. Human fatty liver disease: old questions and new insights[J]. Science,2011,332(6037):1519-1523.
ANJANI K, LHOMME M, SOKOLOVSKA N, et al. Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity[J]. J Hepatol,2015,62(4):905-912.
RESS C, KASER S. Mechanisms of intrahepatic triglyceride accumulation[J]. World J Gastroenterol,2016,22(4):1664-1673.